SHORT REPORTS Willebrand factor in von Willebrand's disease
The diagnosis of von Willebrand's disease (VWD) is usually made from the prolonged bleeding times and reduced plasma clotting factor VIII (F VIII C) activities of persons with a positive family history. The characteristically prolonged rise in F VIII C after plasma or cryoprecipitate treatment confirms the diagnosis. Recent discoveries have shown reduced levels of antigenic factor VIII (F VIII Ag) and diminished glass-induced adhesion and ristocetin induced aggregation of platelets in V.W.D. plasma. All these defects are corrected in vitro and in vivo by fractions of normal plasma which are closely linked to F VIII Ag. These fractions contain "(von) Willebrand factor" (F VIII W.F.), whose concentration is very low in VWD plasma and which can be assayed using its ability to cause platelets to aggregate with ristocetin' -a phenomenon of pharmacological rather than physiological significance. The existence of atypical families indicates that there may be several "molecular" variants-for example, some with normal F VIII Ag but low F VIII W.F.
Kernoff et al.2 found that factor VIII treatment to VWD patients was followed by a persistent rise of high-molecular weight F VIII Ag and F VIII C. On the other hand, Bennett et al.3 found that whereas such treatment was followed by persistently high F VIII C activity, the F VIII Ag levels fell rapidly; and Sinus bradycardia following treatment with hydergine for cerebrovascular insufficiency
The use of Hydergine (dihydroergotoxine mesylate) in the treatment of patients suffering from dementia as a result of cerebrovascular insufficiency has been the subject of recent reports.' 2 Studies of drugs used in treating dementia using the automated pair matching test3 included the action of Hydergine in a few patients with dementia resulting from cerebrovascular disease (multi-infarction dementia). In a small trial in which Hydergine was given to eight patients three developed a serious degree of sinus bradycardia associated with a general deterioration in their condition necessitating ending the treatment. An ECG confirmed the presence of sinus bradycardia in all three patients; the deterioration in their general health consisted of withdrawal, listlessness, refusal of food, and general apathy. The pulse reverted to normal and the symptoms disappeared within two days of ending the drug.
Discussion
Hydergine contains 1-5 mg of mesylates of dihydrogenated alkaloids of dihydroergokryptine. The substance is thought to have a profound alpha-blocking action. It has also been suggested that it may have beta-adrenergic blocking effects.4 The bradycardiac effect of Hydergine is mentioned in earlier European literature particularly in relation to the use of Hydergine in peripheral vascular disease, but we have been unable to find a mention in the more recent literature in this country referring to its use in cerebrovascular insufficiency. Further research into the action of Hydergine on the heart rate would be of interest. We feel the development of this complication in three out of eight patients treated with Hydergine associated with severe systemic symptoms is of sufficient importance to report these cases.
We thank Mrs J Newman, SRN, and Mrs P Southward, SRN, for helping with the running of the trial. SLE precipitated by antibodies in a patient with Sjogren's syndrome and rheumatoid arthritis Typical rheumatoid arthritis and systemic lupus erythematosus (SLE) are often considered as separate diseases with different prognoses and treatments. Sj0gren's syndrome has been reported in association with both diseases.' It has been suggested, however, that SLE and rheumatoid arthritis may well represent opposite ends of a spectrum of connective tissue diseases and that overlap cases combining features of both diseases may occur.2 This latter concept is illustrated by the patient reported here, in whom a disease with the typical, clinical, and serological features of SLE was precipitated by antibiotics on two occasions but who had otherwise typical rheumatoid arthritis with Sj0gren's syndrome in the intervening period.
Case History
Mrs AB, aged 42 in April 1973, developed polyarthritis, fever and a chest infection two weeks after treatment for a sore throat with a 12 day course of co-trimoxazole. She had a history of respiratory tuberculosis treated with chemotherapy in 1961, while her mother had had Sjogren's syndrome and rheumatoid arthritis. After further treatment elsewhere with co-trimoxazole and rifampicin, ethambutol, and isoniazid she became ill with worsening of her polyarthritis and pericarditis. LE cells were seen in the blood film; the titre of serum antinuclear factor was 1/1000, and that of rheumatoid factor 1/256, while DNA binding 280' (borderline abnormal). SLE was diagnosed, all therapy stopped, and high dose prednisolone started. She improved clinically and steroids were tailed off. During follow-up over the next year at the Centre for Rheumatic Diseases she developed symptomatic Sjogren's syndrome with typical ocular and oral manifestations. She continued to have intermittent peripheral joint pain and stiffness and developed synovial hypertrophy of the metacarpophalangeal and proximal interphalangeal joints of the hands and x-ray changes of periarticular osteoporosis and juxtaarticular erosions.
She was managed with non-steroidal anti-inflammatory drugs and by December 1974 her serum antinuclear factor had become negative, DNA binding 00%, and the titre of rheumatoid factor 1/1025. She remained generally well otherwise until April 1975, when she again was treated with cotrimoxazole at home for a sore throat. After this she remained generally unwell for a month until she was admitted to hospital in May with fever and signs of a left basal pneumonia. She was then treated with co-trimoxazole initially and rapidly became worse with confusion, pyrexia, and extreme weakness. Laboratory tests showed DNA binding of 60% with an antinuclear factor titre of 1/1000, complement C3 160% (normal 75-150%h), complement C4 690o (normal 31-550/ ) . Co-trimoxazole was stopped and she was again treated with high dose steroids and improved clinically in parallel with a change in her abnormal serological indices.
Discussion
This patient developed the multi-system features of SLE on two occasions after the administration of antibiotics, including cotrimoxazole. Sulphonamides, like penicillin, have been reported to precipitate SLE in those predisposed,3 and it seems likely that they, rather than the trimethoprin component of co-trimoxazole, were responsible in this case. Antibodies to native DNA4 were demonstrated during this patient's second illness and, as they are not usually found in drug-induced SLE5 their presence in the patient may represent true SLE activated in a susceptible patient by drugs. 
